![5-[2-Ethoxy-5-[(4-methyl-4-oxidopiperazin-1-yl)sulfonyl]phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-p…](https://static.cymitquimica.com/products/86/img/MM0254.04.png "Click to enlarge")
5-[2-Ethoxy-5-[(4-methyl-4-oxidopiperazin-1-yl)sulfonyl]phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (Sildenafil N-Oxide)
CAS: 1094598-75-0
Ref. 86-MM0254.04
| 100mg | 1,385.00 € |
Estimated delivery in United States, on Tuesday 10 Dec 2024
Product Information
Name:
5-[2-Ethoxy-5-[(4-methyl-4-oxidopiperazin-1-yl)sulfonyl]phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (Sildenafil N-Oxide)
Controlled Product
Synonyms:
- Sildenafil Citrate Imp. B (EP)
- Sildenafil Imp. B (EP)
- 5-[2-Ethoxy-5-[(4-methyl-4-oxidopiperazin-1-yl)sulfonyl]phenyl]-1-methyl-3-propyl-6,7-dihydro-1Hpyrazolo[4,3-d]pyrimidin-7-one
- Sildenafil N-Oxide
- Sildenafil Citrate Impurity B
- Sildenafil Impurity B
Notice:
Our products are intended for lab use only. For any other use, please contact us.
Brand:
Mikromol
Long term storage:
Notes:
Chemical properties
Molecular weight:
490.58
Formula:
C22H30N6O5S
Color/Form:
Neat
InChI:
InChI=1S/C22H30N6O5S/c1-5-7-17-19-20(26(3)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)33-6-2)34(31,32)27-10-12-28(4,30)13-11-27/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)
InChI key:
InChIKey=JQGFLCMKCZPSEC-UHFFFAOYSA-N
SMILES:
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CC[N+](C)([O-])CC4)ccc3OCC)nc12
MDL:
Melting point:
Boiling point:
Flash point:
Density:
Concentration:
EINECS:
Merck:
HS code:
Technical inquiry about: 86-MM0254.04 5-[2-Ethoxy-5-[(4-methyl-4-oxidopiperazin-1-yl)sulfonyl]phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (Sildenafil N-Oxide)
Please use instead the cart to request a quotation or an order
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
